Printer Friendly

New Nymox Second-Hand Smoke Study Begins for NicAlert.

Business Editors/Health & Medical Writers

MAYWOOD, N.J.--(BUSINESS WIRE)--Aug. 20, 2002

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that a large new prospective study of its NicAlert(TM) test for tobacco exposure has begun at West Virginia University. The investigation is being led by Dr. Norman Montalto.

Dr. Montalto is Associate Professor in the Department of Family Medicine at West Virginia University. He has been actively involved for over a decade in pharmaceutical and tobacco product addiction research, smoking cessation, and clinical trials. Dr. Montalto has numerous peer-reviewed publications in the field, and has served as expert speaker, reviewer and consultant for major pharmaceutical companies that specialize in cessation products. Dr. Montalto is Director of the Freedom From Tobacco Program at the Charleston Area Medical Center and Physician Advisor for Tobacco Cessation Benefit Programs for Medicaid, the Public Employees Insurance Agency (PEIA), and the Medical Director of the State Tobacco Quit-Line.

Second-hand smoke or environmental tobacco smoke (ETS) is increasingly being recognized around the world as a serious but preventable public health risk. Second-hand smoke has been linked to cancer and to increased risk of heart disease and stroke.

NicAlert(TM) is Nymox's simple-to-use test for the determination of tobacco use or exposure. It uses either urine or saliva samples to detect levels tobacco exposure for smokers and non-smokers. NicAlert(TM) is currently being used in research programs into tobacco used and exposure and is being marketed in the United States and Japan as a test to determine whether a person, such as a teenager, student, athlete or insurance applicant is using a tobacco product.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 20, 2002
Words:363
Previous Article:Center For Jewish History To Mark 9/11 With `Days of Awe' Panel Discussion; Three Jewish Chaplains To Offer Personal Reflections.
Next Article:Think Dynamics Appoints Former Compaq Executive to Advisory Board; Ashok Shah to Share Insight and Experience as Think Dynamics Continues with...


Related Articles
Study links secondhand smoke to heart disease.
DATA: OTHERS' SMOKE WORSE THAN FEARED.
Nymox's NicAlert Potential Aid in Second-Hand Smoke Child Custody Cases.
World Health Organization Links Second Hand Smoke to Cancer; Nymox's NicAlert Test Offers a Unique Tool for Tobacco Control Programs.
Second-Hand Smoke Implicated in Heart Disease and Stroke; Nymox NicAlert Able to Detect Second-Hand Smoke Exposure.
Nymox's NicAlert Can Detect Second-Hand Smoke Exposure in the Home.
American Respiratory Alliance Will Use Nymox's NicAlert as its Official Test Agent in Smoking Cessation Programs.
New Nymox Product Study Data to be Presented at World Conference on Tobacco.
Death clock: secondhand smoke hype.
NicAlert(TM) Study in Children to be Presented at American Thoracic Society Conference in San Francisco.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters